The Regulatory Capture Revolving Door: When Tobacco Regulators Become Tobacco Consultants

In 2021, a senior FDA official who had overseen the agency's tobacco product review process left the agency to join a law firm that represents tobacco and vaping companies in their regulatory matters before the FDA. The departure was legal—the official complied with the required cooling-off period—but it illustrated a dynamic that is pervasive in tobacco regulation: the movement of expertise, relationships, and institutional knowledge between the regulatory agency and the regulated industry. The revolving door is not unique to tobacco regulation—it is a feature of the regulatory state across sectors—but it is particularly consequential in a field where the regulatory decisions determine which products reach the market, which companies survive, and ultimately, how many people die from smoking-related disease. The human capital that flows through the revolving door shapes regulatory outcomes in ways that are difficult to measure but impossible to ignore.

The mechanisms by which the revolving door influences regulatory outcomes are both direct and indirect. The direct mechanism is the most intuitive: regulators who anticipate future employment in the industry may be influenced—consciously or unconsciously—to make decisions that are favorable to potential future employers. The indirect mechanisms are more subtle but perhaps more consequential. The prospect of future industry employment affects who applies for regulatory positions in the first place—individuals who are ideologically hostile to the industry are less likely to see a career path that leads to industry, and may be deterred from regulatory service. The shared professional culture between regulators and industry—the common educational backgrounds, the overlapping professional networks, the shared language of risk assessment and cost-benefit analysis—creates a cognitive framework in which industry perspectives are more legible and persuasive than public health perspectives. The revolving door does not require corruption to be effective. It operates through the normal functioning of professional networks and career incentives—which makes it harder to identify and harder to regulate.

The revolving door in tobacco regulation has a particular historical context. For decades, the tobacco industry was excluded from the normal regulatory process—tobacco products were explicitly exempted from FDA authority until the 2009 Tobacco Control Act, and the industry's historical misconduct made it a pariah in public health circles. The creation of the FDA's Center for Tobacco Products (CTP) in 2009 brought the industry into the regulatory fold, and with it, the normal dynamics of regulatory engagement—including the revolving door. The CTP, a relatively new regulatory agency, has had to build its expertise rapidly, and much of that expertise has been acquired from the industry it regulates (through consultations, advisory committee service, and the scientific literature that the industry funds). The CTP's institutional culture, shaped by this recruitment dynamic, has been more industry-engaged than the public health advocacy community would prefer—a source of persistent tension between the agency and the advocates who fought for its creation.

The revolving door also operates in the other direction: tobacco control advocates and researchers have moved into regulatory positions at the FDA, bringing with them the perspectives and priorities of the advocacy community. This 'reverse revolving door' is less discussed but equally consequential. The FDA officials who came from tobacco control advocacy backgrounds have been instrumental in the agency's more aggressive regulatory actions—the Juul enforcement, the proposed menthol ban, the low-nicotine product standard. The reverse revolving door ensures that the regulatory agency is not captured exclusively by industry perspectives—but it also ensures that the agency is a battleground for the same polarized debate that characterizes the broader nicotine policy discourse. The CTP is not a neutral arbiter between industry and public health. It is an institution whose personnel reflect the competing perspectives of the constituencies that surround it, and whose decisions are shaped by the balance of those perspectives within the agency at any given time.

The regulatory framework for managing the revolving door is primarily procedural—cooling-off periods, recusal requirements, ethics disclosures—and is widely regarded as inadequate. A former regulator who joins an industry law firm is prohibited from representing clients before their former agency for a specified period (typically one to two years), but they can provide strategic advice, prepare submissions, and shape the arguments that other lawyers will present—activities that are difficult to monitor and essentially impossible to prohibit. The cooling-off period is a speed bump, not a barrier. More fundamentally, the procedural approach to revolving-door regulation treats the problem as one of individual conflicts of interest rather than one of institutional culture. The fact that a regulator can leave the agency and immediately command a premium salary from the industry they regulated is not just a conflict-of-interest problem. It is a signal about the incentives that shape regulatory careers—and that signal is received by every regulator who is still at the agency, considering their own career trajectory.

Addressing the revolving door requires more than stricter cooling-off periods. It requires making regulatory service a viable career endpoint, not a stepping stone—by paying regulators salaries that are competitive with the private sector, by providing career advancement paths within the regulatory agency that are comparable to those in industry, and by cultivating an institutional culture that values regulatory service as a public good rather than as a credential for future private-sector employment. These measures are expensive and politically difficult—raising civil-service salaries requires congressional action, and the political environment for expanding the regulatory state is not favorable. But the alternative—a regulatory agency whose personnel view their positions as temporary assignments between industry jobs, and whose decisions are shaped by the career incentives that the revolving door creates—is a regulatory agency that cannot effectively regulate. The revolving door is not the only threat to regulatory integrity, but it is among the most corrosive—and among the least addressed.

Shareable insight: The revolving door between tobacco regulators and the tobacco industry doesn't require corruption to be effective. It operates through career incentives, professional networks, and the shared cognitive framework that develops when regulators and industry professionals share the same educational backgrounds and career trajectories. The cooling-off periods that are supposed to manage the revolving door are speed bumps, not barriers. The deeper problem is institutional culture—and it is almost entirely unaddressed.